DUBLIN--(BUSINESS WIRE)--The "Anti-CD33 Antibody - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD33 Antibody development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Scope
- Provides a snapshot of the therapeutics pipeline activity for Anti-CD33 Antibody
- Features the Anti-CD33 Antibody pipeline across the complete product development cycle including all clinical and non-clinical stages
- Offers detailed therapeutic product profiles of Anti-CD33 Antibody with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
- Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
- Coverage of dormant and discontinued pipeline projects across Anti-CD33 Antibody
Companies Featured
- Affimed Therapeutics
- Boehringer Ingelheim
- PersonGen Biomedicine
- ImmunoGen
Key Topics Covered
1. Report Introduction
2. Anti-CD33 Antibody - Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Anti-CD33 Antibody
4. Comparative Analysis
5. Anti-CD33 Antibody Pipeline Products in Clinical Stages
5.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
Other product profiles in the detailed report..
6. Anti-CD33 Antibody Pipeline Products in Non-clinical Stages
6.1 Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment: Active Products
- Pipeline Assessment by Route of Administration
- Pipeline Assessment by Stage and Route of Administration
- Pipeline Assessment by Molecule Type
- Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline Products
8.1 Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Reason for dormancy/discontinuation
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ccc5jp/anticd33?w=4
